Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Global publication plans

- PMLiVE

Alzheimer’s Research UK welcomes government’s pledge to tackle dementia crisis

The commitments form part of a new UK-wide strategy to alleviate pressures on the health system

- PMLiVE

Eli Lilly announces $450m investment in US manufacturing site

In December 2022 increased demand resulted in a short supply of two of its diabetes drugs

- PMLiVE

Pistoia Alliance launches free guide on implementing FAIR principles in clinical data

The guide was co-authored by leading experts from Roche, AstraZeneca and others

- PMLiVE

World Health Organization launches $2.54bn emergency health appeal

The organisation is currently responding to 54 health crises across the world

- PMLiVE

EU outlines measures to mitigate antibiotic shortage across Europe

An unseasonably early upsurge in respiratory infections has led to the increase in demand

- PMLiVE

EC launches cancer imaging initiative to accelerate innovation and early diagnosis

Researchers will have better access to high-quality resources and databases

- PMLiVE

Digital technology: a significant change in healthcare innovation

By Megan Allen

- PMLiVE

Neurodiversity and healthcare communications – do we know enough and do we do enough?

By Robert Goodwin

Virtual Steering Committee & Peer Influence Program

In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program.

Impetus Digital

- PMLiVE

Alzheimer’s Society urges UK government to deliver on dementia plan

The strategy, announced in May last year, includes doubling dementia research funding

- PMLiVE

Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer

The investigational treatment regimen met its primary endpoint of overall survival

- PMLiVE

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

The BTK inhibitor demonstrated better results than Imbruvica, a standard of care treatment in CLL

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links